Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2018 3
2019 2
2020 2
2021 1
2022 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Bullous eruption in a pluripathological patient.
Rusiñol L, Carmona-Rocha E, Spertino J. Rusiñol L, et al. Among authors: spertino j. Int J Dermatol. 2023 May;62(5):e312-e313. doi: 10.1111/ijd.16590. Epub 2023 Jan 22. Int J Dermatol. 2023. PMID: 36683133 No abstract available.
Epidermolysis bullosa acquisita induced by atezolizumab.
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Carmona-Rocha E, et al. Among authors: spertino j. J Dtsch Dermatol Ges. 2023 Nov;21(11):1407-1409. doi: 10.1111/ddg.15203. Epub 2023 Sep 1. J Dtsch Dermatol Ges. 2023. PMID: 37658659 No abstract available.
[Epidermolysis bullosa acquisita ausgelöst durch Atezolizumab].
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Carmona-Rocha E, et al. Among authors: spertino j. J Dtsch Dermatol Ges. 2023 Nov;21(11):1407-1409. doi: 10.1111/ddg.15203_g. J Dtsch Dermatol Ges. 2023. PMID: 37946658 German. No abstract available.
Definition of Recurrent Chronic Spontaneous Urticaria.
Melé-Ninot G, Serra-Baldrich E, Curto-Barredo L, Figueras-Nart I, Spertino J, Expósito-Serrano V, García-Navarro X, Guilabert A, Bielsa-Marsol I, Giménez-Arnau AM. Melé-Ninot G, et al. Among authors: spertino j. Acta Derm Venereol. 2020 Sep 23;100(16):adv00267. doi: 10.2340/00015555-3633. Acta Derm Venereol. 2020. PMID: 32926176 Free PMC article. No abstract available.
Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab.
Spertino J, Curto Barredo L, Rozas Muñoz E, Figueras Nart I, Gimenez Arnau A, Serra Baldrich E, Bonfill-Ortí M, Expósito-Serrano V, Guilabert A, Melé Ninot G, Villar Buil M, Garcias Ladaria J, García Navarro X, Vilavella M, Bielsa Marsol I, Aparicio Ortiz G, Baliu Piqué C, Álvarez Abella A, Lamas Domenech N, Mascaró JM, Gómez S, Torné Gutiérrez JI, Vicente Villa A, Gimenez Arnau A. Spertino J, et al. Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):771-776. doi: 10.1016/j.ad.2018.07.005. Epub 2018 Aug 11. Actas Dermosifiliogr (Engl Ed). 2018. PMID: 30107875 English, Spanish.
Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
Melé-Ninot G, Curto-Barredo L, Bonfill-Ortí M, Expósito-Serrano V, Munera-Campos M, Figueras Nart I, Riquelme-Mc Loughlin C, Gómez-Armayones S, Spertino J, Serra-Baldrich E. Melé-Ninot G, et al. Among authors: spertino j. Australas J Dermatol. 2024 Mar;65(2):153-162. doi: 10.1111/ajd.14196. Epub 2023 Dec 6. Australas J Dermatol. 2024. PMID: 38058123
The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.
Cubiró X, Spertino J, Rozas-Muñoz E, Serra-Baldrich E, Puig L. Cubiró X, et al. Among authors: spertino j. Actas Dermosifiliogr (Engl Ed). 2019 May;110(4):289-296. doi: 10.1016/j.ad.2018.09.009. Epub 2018 Oct 22. Actas Dermosifiliogr (Engl Ed). 2019. PMID: 30360885 Review. English, Spanish.
Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
Melé-Ninot G, Serra-Baldrich E, Spertino J, Guilarte M, Ribó González P, Lleonart-Bellfill R, Figueras-Nart I, Bonfill-Ortí M, Depreux N, Sala-Cunill A, Bielsa-Marsol I, Baliu-Piqué C, Sanmartín-Novell V, Garcia-Navarro X, Expósito-Serrano V, Garnica-Velandia D, Diaz-Sarrió MC, Gómez-Armayones S, Gich Saladich I, Giménez-Arnau A. Melé-Ninot G, et al. Among authors: spertino j. Eur J Dermatol. 2022 Sep 1;32(5):629-631. doi: 10.1684/ejd.2022.4334. Eur J Dermatol. 2022. PMID: 36468733 English.
Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, Gómez Armayones S, Serra-Baldrich E, Spertino J, Bonfill Ortí M, Figueras Nart I, Melé-Ninot G, Baliu-Piqué C, Sala Cunill A, Labrador-Horrillo M, Guilabert Vidal A, Fernández Chico N, Giménez-Arnau AM. Exposito-Serrano V, et al. Among authors: spertino j. Br J Dermatol. 2021 Jan;184(1):167-168. doi: 10.1111/bjd.19425. Epub 2020 Sep 2. Br J Dermatol. 2021. PMID: 32730636 No abstract available.
Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria.
Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G, Cubiró X, Bonfill-Ortí M, Garcias-Ladaria J, Villar M, García-Navarro X, Bielsa-Marsol I, Vilavella M, Aparicio G, Baliu-Piqué C, Álvarez A, Lamas-Domenech N, Duran-Jordà X, Serra-Baldrich E, Giménez-Arnau A. Curto-Barredo L, et al. Among authors: spertino j. Br J Dermatol. 2018 Jul;179(1):210-212. doi: 10.1111/bjd.16379. Epub 2018 Apr 25. Br J Dermatol. 2018. PMID: 29368377 No abstract available.
13 results